Novavax Inc (NVAX) 4.32 $NVAX
Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 12:30PM CDT
Clinical-stage, synthetic-vaccine maker Inovio Pharmaceuticals posted first-quarter earnings this morning and gave a number of clinical updates for its growing DNA-vaccine platform. Here is what you need to know from today's release. Business...
One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response
GlobeNewswire - Mon May 12, 8:16AM CDT
-- Sustained levels of RSV F antibody and palivizumab-competing antibody responses demonstrated over a 4 to 6 month period
Key Takeaways From Novavax's First-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 7:48AM CDT
Earnings season for developmental-stage biotechs is often a non-event. These companies tend to have little in the way of earnings, and major clinical updates are generally given at the time certain milestones are achieved. So it's not surprising that...
Novavax Reports First-Quarter 2014 Financial Results
Thomson Reuters ONE - Wed May 07, 10:17PM CDT
GAITHERSBURG, Md., May 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the first quarter ended March 31, 2014.
Novavax Appoints Sven Andreasson as Senior Vice President, Corporate Development
Thomson Reuters ONE - Tue May 06, 3:33PM CDT
GAITHERSBURG, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Sven Andreasson to the position of Senior Vice President, Corporate Development, effective June 2, 2014. Mr. Andreasson will be responsible for identifying, prioritizing and evaluating new strategic opportunities that leverage the company's core strengths and growth initiatives.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun May 04, 9:00AM CDT
It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. ...
Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.
Novavax to Report First Quarter Financial Results on May 7, 2014
Thomson Reuters ONE - Thu May 01, 11:14AM CDT
GAITHERSBURG, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014 after the close of the U.S. financial markets.
New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Thomson Reuters ONE - Wed Apr 30, 7:02AM CDT
University of Maryland School of Medicine Study Published in Vaccine Highlights First Potential Effective Means for Preventing MERS Coronavirus Outbreak
Morning Review on Top Gainers -- Research on Banco Santander Brasil, Novavax, Cadence Design Systems, and Amicus Therapeutics
PR Newswire - Wed Apr 30, 7:00AM CDT
The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session 0.53% higher at 16,535.37, and the S&P 500 edging 0.48% higher to finish the trading session at 1,878.33. During the session gains in the Financials, Information Technology and Materials sectors positively impacted the broader market, while some retraction came in from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Banco Santander Brasil S.A. (NYSE: BSBR), Novavax Inc. (NASDAQ: NVAX), Cadence Design Systems Inc. (NASDAQ: CDNS) and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free technical research on BSBR, NVAX, CDNS and FOLD can be downloaded upon signing up at:
Why XOMA, Zillow, and Novavax Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 4:15PM CDT
High hopes for earning season continued to fuel the S&P 500 upward on Tuesday, with the broad-based index advancing for the ninth time in the past 11 sessions. Economic data, on the other hand, was good, but not great. First up, The...
Why Novavax Inc. Shares Took Flight
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 2:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Novavax , a biopharmaceutical company...
Hot Stock: Novavax, Shares Gain 7.6% (NVAX)
Comtex SmarTrend(R) - Tue Apr 29, 12:45PM CDT
Novavax (NASDAQ:NVAX) is one of today's best performing low-priced stocks, up 7.6% to $4.24 on 1.2x average daily volume. Novavax has traded 5.9 million shares thus far today, vs. average volume of 4.8 million shares per day. The stock has outperformed the Dow (7.6% to the Dow's 0.6%) and outperformed the S&P 500 (7.6% to the S&P's 0.5%) during today's trading.
Why Novavax (NVAX) Stock Is Higher Today
at The Street - Tue Apr 29, 8:25AM CDT
Shares of Novavax (NVAX) are up 8.12% to $4.26 in pre-market trade after the clinical stage biopharmaceutical company said its respiratory ailment vaccine candidate for women of childbearing age in a Phase 2 study showed positive results.
Today’s Top Health Care Stories: Novavax, Merck, and Bristol-Myers Squibb
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 29, 8:18AM CDT
Let's take a quick look at three stocks which could loom large in health care headlines this Tuesday morning -- Novavax , Merck , and Bristol-Myers Squibb . Novavax shows positive top-line data for its RSV-F vaccine candidate Novavax...
Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 12:30PM CDT
Clinical-stage, synthetic-vaccine maker Inovio Pharmaceuticals posted first-quarter earnings this morning and gave a number of clinical updates for its growing DNA-vaccine platform. Here is what you need to know from today's release. Business...
One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response
GlobeNewswire - Mon May 12, 8:16AM CDT
-- Sustained levels of RSV F antibody and palivizumab-competing antibody responses demonstrated over a 4 to 6 month period
Key Takeaways From Novavax's First-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 7:48AM CDT
Earnings season for developmental-stage biotechs is often a non-event. These companies tend to have little in the way of earnings, and major clinical updates are generally given at the time certain milestones are achieved. So it's not surprising that...
Novavax Reports First-Quarter 2014 Financial Results
Thomson Reuters ONE - Wed May 07, 10:17PM CDT
GAITHERSBURG, Md., May 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the first quarter ended March 31, 2014.
Novavax Appoints Sven Andreasson as Senior Vice President, Corporate Development
Thomson Reuters ONE - Tue May 06, 3:33PM CDT
GAITHERSBURG, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Sven Andreasson to the position of Senior Vice President, Corporate Development, effective June 2, 2014. Mr. Andreasson will be responsible for identifying, prioritizing and evaluating new strategic opportunities that leverage the company's core strengths and growth initiatives.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun May 04, 9:00AM CDT
It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. ...
Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.
Novavax to Report First Quarter Financial Results on May 7, 2014
Thomson Reuters ONE - Thu May 01, 11:14AM CDT
GAITHERSBURG, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014 after the close of the U.S. financial markets.
New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Thomson Reuters ONE - Wed Apr 30, 7:02AM CDT
University of Maryland School of Medicine Study Published in Vaccine Highlights First Potential Effective Means for Preventing MERS Coronavirus Outbreak
Morning Review on Top Gainers -- Research on Banco Santander Brasil, Novavax, Cadence Design Systems, and Amicus Therapeutics
PR Newswire - Wed Apr 30, 7:00AM CDT
The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session 0.53% higher at 16,535.37, and the S&P 500 edging 0.48% higher to finish the trading session at 1,878.33. During the session gains in the Financials, Information Technology and Materials sectors positively impacted the broader market, while some retraction came in from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Banco Santander Brasil S.A. (NYSE: BSBR), Novavax Inc. (NASDAQ: NVAX), Cadence Design Systems Inc. (NASDAQ: CDNS) and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free technical research on BSBR, NVAX, CDNS and FOLD can be downloaded upon signing up at:
Why XOMA, Zillow, and Novavax Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 4:15PM CDT
High hopes for earning season continued to fuel the S&P 500 upward on Tuesday, with the broad-based index advancing for the ninth time in the past 11 sessions. Economic data, on the other hand, was good, but not great. First up, The...
Why Novavax Inc. Shares Took Flight
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 2:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Novavax , a biopharmaceutical company...
Hot Stock: Novavax, Shares Gain 7.6% (NVAX)
Comtex SmarTrend(R) - Tue Apr 29, 12:45PM CDT
Novavax (NASDAQ:NVAX) is one of today's best performing low-priced stocks, up 7.6% to $4.24 on 1.2x average daily volume. Novavax has traded 5.9 million shares thus far today, vs. average volume of 4.8 million shares per day. The stock has outperformed the Dow (7.6% to the Dow's 0.6%) and outperformed the S&P 500 (7.6% to the S&P's 0.5%) during today's trading.
Why Novavax (NVAX) Stock Is Higher Today
at The Street - Tue Apr 29, 8:25AM CDT
Shares of Novavax (NVAX) are up 8.12% to $4.26 in pre-market trade after the clinical stage biopharmaceutical company said its respiratory ailment vaccine candidate for women of childbearing age in a Phase 2 study showed positive results.
Today’s Top Health Care Stories: Novavax, Merck, and Bristol-Myers Squibb
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 29, 8:18AM CDT
Let's take a quick look at three stocks which could loom large in health care headlines this Tuesday morning -- Novavax , Merck , and Bristol-Myers Squibb . Novavax shows positive top-line data for its RSV-F vaccine candidate Novavax...
